approval_status	approval_org	description	indication	cancer_type	biomarker	therapy_drug	therapy_approach	therapy_strategy	therapy_type	approval_url	publication_date
Regulatory approval	fda	The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).	Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.	Invasive Breast Carcinoma	ER positive [present], HER2-negative [present]	['Abemaciclib', 'Tamoxifen']	Combination therapy	['CDK4/6 inhibition', 'Estrogen receptor inhibition']	['Targeted therapy', 'Hormone therapy']	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf	3/3/23